SCHEMBL4669533

SCHEMBL4669533

Cc1ccc(S(=O)(=O)NC2CCOC2=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
CYP3A4 P08684 3/20 0.53
TSHR P16473 1/20 0.53
HTT P42858 1/20 0.50
PIK3CD O00329 1/20 0.46
PIK3CB P42338 1/20 0.46
PIK3CG P48736 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7417712 1.00 ALDH1A1 (0.53) ALDH1A1CYP3A4TSHRHTTPIK3CD
SCHEMBL9153465 1.00 ALDH1A1 (0.53) ALDH1A1CYP3A4TSHRHTTPIK3CD
SCHEMBL18780344 0.93 ALDH1A1 (0.47) ALDH1A1CYP3A4TSHRHTTPIK3CD
SCHEMBL17329200 0.86 MEN1 (0.56) ALDH1A1CYP3A4POLBMAPTKMT2A
SCHEMBL17329201 0.86 MEN1 (0.56) ALDH1A1CYP3A4POLBMAPTKMT2A
SCHEMBL18780379 0.85 PIK3CD (0.45) PIK3CDPIK3CBPIK3CG
SCHEMBL20334896 0.85 PIK3CD (0.45) PIK3CDPIK3CBPIK3CG
SCHEMBL17329225 0.85 PIK3CD (0.46) PIK3CDPIK3CBPIK3CG
SCHEMBL17329197 0.85 PIK3CD (0.46) PIK3CDPIK3CBPIK3CG
SCHEMBL8839698 0.85 CRHBP (0.47) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1193253-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACIDS KANEKA CORP (JP) 2008-06-25 EP disclosed
EP-1927588-A2 Process for producing optically active azetidine-2-carboxylic acids KANEKA CORPORATION (JP) 2008-06-04 EP disclosed
US-7262308-B2 Process for producing optically active azetidine-2-carboxylic acids KANEKA CORPORATION (JP) 2007-08-28 US disclosed
US-20050043547-A1 Process for producing optically active azetidine-2-carboxylic acids HONDA TATSUYA (JP) 2005-02-24 US disclosed
US-6838567-B1 Process for producing optically active azetidine-2-carboxylic acids KANEKA CORPORATION (JP) 2005-01-04 US disclosed
US-20040171849-A1 Process for producing optically active azetidine-2-carboxylic acid KANEKA CORPORATION (JP) 2004-09-02 US disclosed
EP-1415985-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACID KANEKA CORPORATION (JP) 2004-05-06 EP disclosed
CN-1125064-C 3-pyridyl enantiomers and their use as analgesics ABBOTT LAB (US) 2003-10-22 CN disclosed
EP-0992491-B1 PROCESSES FOR PRODUCING AZETIDINE-2-CARBOXYLIC ACID AND INTERMEDIATES THEREOF KANEKA CORP (JP) 2003-03-05 EP disclosed
EP-0950057-B1 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS ABBOTT LAB (US) 2002-11-13 EP disclosed
US-6432975-B1 AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT TARGACEPT, INC. 2002-08-13 US disclosed
US-6403575-B1 ANTI-INFLAMMATORIES ABBOTT LABORATORIES 2002-06-11 US disclosed
EP-1193253-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACIDS KANEKA CORPORATION (JP) 2002-04-03 EP disclosed
US-6150535-A Processes for producing azetidine-2-carboxylic acid and intermediates thereof KANEKA CORPORATION (JP) 2000-11-21 US disclosed
EP-1047690-A1 HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION Abbott Laboratories (US) 2000-11-02 EP disclosed
US-6133253-A NEURONAL CELL DEATH PREVENTORS AND ANTI-INFLAMMATORIES ABBOTT LABORATORIES (US) 2000-10-17 US disclosed
EP-0992491-A1 PROCESSES FOR PRODUCING AZETIDINE-2-CARBOXYLIC ACID AND INTERMEDIATES THEREOF KANEKA CORPORATION (JP) 2000-04-12 EP disclosed
CN-1245496-A 3-pyridyl enantiomers and their use as analgesics ABBOTT LAB (US) 2000-02-23 CN disclosed
WO-1999032480-A1 HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LABORATORIES (US) 1999-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171849-A1 Process for producing optically active azetidine-2-carboxylic acid HBB, ADCY2, ADCY9 ALDH1A1 587/4885CYP3A4 526/4885TSHR 1514/4885
US-20050043547-A1 Process for producing optically active azetidine-2-carboxylic acids AZI2, ALAD, HBB ALDH1A1 1133/4885CYP3A4 339/4885TSHR 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.